Stephens initiated coverage of BrightSpring Health (BTSG) with an Overweight rating and $44 price target In aggregate, BrightSpring has delivered a relatively heightened growth profile post-IPO fueled by organic strength in the core Pharmacy Solutions segment supplemented by M&A expansion into its higher margin Provider Services segment, the analyst tells investors in a research note. The firm added that sustaining the premium growth profile contemplates leading market positioning in core business as new drugs/regimens launch and existing therapies evolve.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health initiated with an Overweight at Stephens
- BrightSpring Health price target raised to $41 from $38 at BofA
- BrightSpring Health Services: Strategic Growth and Expansion Drive Promising Outlook
- BrightSpring Health initiated with an Outperform at William Blair
- BrightSpring Health Services: A Leader in Integrated Healthcare with Strong Growth Potential